haftada basari gorulme orani, NNRTI
(p=0.001) ve PI (p=0.001) temelli rejim kullanilanlardan anlamli olarak yuksektir.
The combination of the INSTI DTG plus the NNRTI
RPV may be considered as an alternative (5).
Factors associated with VF after age 10 * Sex Male 1 Female 1.44 0.64-3.24 0.378 Type of regimen NNRTI-based 1 PI-based 0.75 0.25-2.27 0.612 Age at ART start (years) 1.11 0.93-1.32 0.232 Programme year 2002 1 2003 1.52 0.54-4.25 0.428 2004 1.51 0.37-6.07 0.563 2005 2.20 0.41-11.98 0.360 Previous VF <10 years old 3.20 1.05-9.75 0.040 CD4+ <350 cells/[micro]L at 4.05 1.04-15.82 0.044 age 10 VF = viral failure; HR = hazard ratio; CI = confidence interval; NNRTI
= non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; ART = antiretroviral therapy; VL = viral load.
Bu hastalarin ikisi PI, biri NNRTI
bazli rejim almaktaydi.
These second- or third-line regimens following PI-based ART usually include integrase strand transfer inhibitors (INSTIs), a PI (older or new generation) and possibly an NNRTI
For the 27 RT sequences evaluated we observed NNRTI
resistance associated mutations in 11 of the 27 sequences (40.7%).
Side effect profile must be kept in mind while choosing any NNRTI
PI mutations detected were L90M, L10F, NRTI mutations included M41L, A62V, M184V, D67N, L210W, T215Y and K219N and NNRTI
mutations were K101Q and Y181I.
In terms of the NNRTI
class, EFV was the most used (68.1%).
In relation to the pharmacological treatment, the 16.7% of patients receiving IP/r were taking lopinavir/ritonavir and almost all of the 83.3% of individuals who received NNRTI
were taking efavirenz; nevertheless we did not find any correlation between antiretroviral classes and the levels of the analyzed parameters, perhaps due to the short period of therapy using.
These include: an INSTI, a boosted PI, or, in some situations, an NNRTI
. The DHHS guidelines panel currently recommends 6 different ART combinations as first-line treatment in treatment-naive patients (table 2).
The recommended regimen based on two NRTI (Nucleoside reverse transcriptase inhibitor) plus one NNRTI
(Non-nucleoside reverse transcriptase inhibitor) or boosted Protease inhibitor.